 Partial response PR observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV recurrentmetastatic RM nasopharyngeal carcinoma NPC; enrollment into forth dose level is ongoing Anticipates clinical program updates from pivotal NAVAL-1 study in EBV relapsedrefractory RR lymphoma and Phase 1b2 trial in EBV RM NPC and other advanced ... The post Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive EBV Solid Tumor Setting... 